Trimethoprim resistance in <i>Escherichia coli</i> exhibits an allele-specific growth advantage.

ABSTRACT: Introduction. The antibiotic trimethoprim has been used to treat urinary tract infection (UTI) since ~1962. Alongside the nitrofurantoin, there are still justified reasons for trimethoprim use, especially in non-pregnant women. Trimethoprim resistance is commonly the result of acquiring the trimethoprim-insensitive dihydrofolate reductase gene: dfrA. Assessment of clinical Escherichia coli isolates from two clinical trials, AnTIC and ALTAR, identified carriage of two copies of dfrA.Hypothesis. The hypothesis tested here was that dual dfrA carriage provided E. coli with a growth advantage.Methodology. Two hundred and seventy-eight clinical isolates from AnTIC/ALTAR were assessed for dfrA carriage. Microplate-based growth assays

SUBMITTER: Spencer A 

PROVIDER: S-EPMC12452031 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature